This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-L060 | Murinized (from Human) anti-MAGEA3 (KKLLTQHFVQENYLEY) T Cell Receptor, pMSGV1 | Human | Murinized (from Human) | KKLLTQHFVQENYLEY | HLA-A2 | retroviral vector | ||
TCR-L061 | Mouse anti-MAGEA3 (EVDPIGHLY) T Cell Receptor, pLXSN | Human | Mouse | EVDPIGHLY | HLA-A1 | retroviral vector | ||
TCR-L062 | Human anti-MAGEA3 (EVDPIGHLY) T Cell Receptor, pMSGV1 | Human | Human | EVDPIGHLY | HLA-A1 | retroviral vector | ||
TCR-L059Z | Murinized anti-MAGEA3 (aa243-258) T cell receptor, pCDTCR1 | Human | Murinized (from Human) | KKLLTQHFVQENYLEY | HLA-A2 | Lentiviral | ||
TCR-L060Z | Mouse anti-MAGEA3 (aa168-176) T cell receptor (Affinity enhanced), pCDTCR1 | Human | Mouse | EVDPIGHLY | HLA-A1 | Lentiviral | ||
TCR-L061Z | Human anti-MAGEA3 (aa168-176) T cell receptor, pCDTCR1 | Human | Human | EVDPIGHLY | HLA-A1 | Lentiviral | ||
TCR-C119Z | Human anti-MAGE-A3 T cell receptor (MAG-IC3), pCDTCR1 | Human | MAG-IC3 | Human | EVDPIGHLY | HLA-A1 | Lentiviral | |
TCR-C120Z | Mouse anti-MAGE-A3 T cell receptor, pCDTCR1 | Human | Mouse | KVAELVHFL | HLA-A*0201 | Lentiviral | ||
TCR-C121Z | Mouse anti-MAGE-A3 (FLWGPRALV) T cell receptor, pCDTCR1 | Human | Mouse | FLWGPRALV | HLA-A*0201 | Lentiviral | ||
TCR-C122Z | Mouse anti-MAGE-A3 (KVAELVHFL) T cell receptor (Affinity enhanced), pCDTCR1 | Human | Mouse | KVAELVHFL | HLA-A*0201 | Lentiviral | ||
TCR-C123Z | Human anti-MAGE-A3 T cell receptor (A10), pCDTCR1 | Human | A10 | Human | aa 168-176 | HLA-A*01 | Lentiviral | |
TCR-C124Z | Human anti-MAGE-A3 T cell receptor (13-18), pCDTCR1 | Human | 13-18 | Human | aa 168-176 | HLA-A*01 | Lentiviral | |
TCR-C125Z | Human anti-MAGE-A3 (EVDPIGHLY) T cell receptor (Affinity enhanced), pCDTCR1 | Human | Human | EVDPIGHLY | HLA-A*01 | Lentiviral | ||
TCR-C126Z | Human anti-MAGE-A3 T cell receptor (6F9), pCDTCR1 | Human | 6F9 | Human | QHFVQENYLEY | HLA-DPB1*04:01 | Lentiviral | |
TCR-C127Z | Human anti-MAGE-A3 T cell receptor (R12C9), pCDTCR1 | Human | R12C9 | Human | QHFVQENYLEY | HLA-DPB1*04:01 | Lentiviral | |
TCR-C128Z | Human anti-MAGE-A3 T cell receptor (ESBI 648), pCDTCR1 | Human | ESBI 648 | Human | aa 167-176 | HLA-A1 | Lentiviral | |
TCR-C129Z | Human anti-MAGE-A3 T cell receptor (TCRVα38/Vβ2), pCDTCR1 | Human | TCRVα38/Vβ2 | Human | KKLLTQHFVQENYLEY | HLA-DP4 | Lentiviral | |
TCR-C130Z | Human anti-MAGE-A3 T cell receptor (TCRVα3/Vβ28), pCDTCR1 | Human | TCRVα3/Vβ28 | Human | ALKVDVEERV | HLA-A2 | Lentiviral | |
TCR-L245 | Human anti-MAGE-A3 T cell receptor, pCDTCR1 | Human | Human | KVAELVHFL | HLA-A*0201 | Lentiviral | ||
TCR-L246 | Human anti-MAGE-A3 T cell receptor, pCDTCR1 | Human | Human | FLWGPRALV | HLA-A*0201 | Lentiviral | ||
TCR-L359 | Human anti-MAGE-A3 T cell receptor (EB81-103), pCDTCR1 | Human | EB81-103 | Human | EVDPIGHLY | HLA-A1 | Lentiviral | |
TCR-L362 | Murinized anti-MAGE-A3 T cell receptor (6F9), pCDTCR1 | Human | 6F9 | Murinized | AA243-258 | HLA-DP*0401 | Lentiviral | |
TCR-L363 | Murinized anti-MAGE-A3 T cell receptor (R12C9), pCDTCR1 | Human | R12C9 | Murinized | AA243-258 | HLA-DP*0401 | Lentiviral |
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.
LEARN MOREAngiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.
LEARN MORETRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.
LEARN MOREThe latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE